Comparative Pharmacology
Head-to-head clinical analysis: ELLA versus PREVEN EMERGENCY CONTRACEPTIVE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELLA versus PREVEN EMERGENCY CONTRACEPTIVE KIT.
ELLA vs PREVEN EMERGENCY CONTRACEPTIVE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective progesterone receptor modulator (SPRM) with antagonistic and partial agonistic activity. Delays or inhibits ovulation, alters endometrial receptivity, and impairs implantation.
The levonorgestrel component is a progestin that inhibits ovulation and fertilization by altering the cervical mucus and endometrial lining, preventing implantation. The ethinyl estradiol component suppresses gonadotropin release, inhibits ovulation, and alters the endometrium.
30 mg orally as a single dose within 120 hours of unprotected intercourse.
The kit contains levonorgestrel 0.75 mg tablets. The regimen is two tablets: one tablet taken orally as soon as possible within 72 hours of unprotected intercourse, followed by a second tablet taken orally 12 hours later.
None Documented
None Documented
Terminal half-life is approximately 24.7 hours (range 20–30 hours), allowing for single-dose emergency contraception.
26 hours (range 17-35 hours; clinical: no significant accumulation with single dose).
Primarily fecal (≈86%) with minimal renal excretion (≈10%). Biliary elimination of metabolites is also significant.
Primarily renal (50-60% as metabolites, <1% unchanged) and fecal (30-40% as metabolites).
Category C
Category C
Emergency Contraceptive
Emergency Contraceptive